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Abstract 
Background: Elevated serum level of adiponectin and insulin as well as decreased serum resistin level can improve 
glucose metabolism. Biochanin A (BCA) is a flavonoid of Soybean that shows antioxidant properties. This study 
was aimed to examine the effect of BCA on fasting blood sugar (FBS), oxidative stress and serum levels of 
adiponectin, resistin and insulin in rats with type 1 diabetes. Materials and Methods: The rats were randomly 
divided into five groups (n=6). BCA was administered orally in doses of 10 and 15 mg/kg of body weight. Insulin, 
resistin and adiponectin were measured using ELISA kits. The activity of Gamma-Glutamyltransferase (GGT), 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and the levels of Glutathione (GSH) were 
examined. Results: The results showed that BCA treatment significantly reduced the FBS level in diabetic rats 
(p<0.05). Serum insulin was significantly increased in the BCA treated diabetic rats (p<0.05). Moreover, GGT 
activity and GSH was significantly increased in treated rats (p<0.05). Our findings revealed that the administration 
of BCA significantly increased the serum adiponectin (p<0.05). Additionally, serum resistin levels were remarkably 
decreased in treated rats (p<0.05). Conclusion: Taken together, BCA represents a natural phytoestrogen that has an 
important role in improvement of glucose metabolism by regulating of adipokines secretion. Our findings slso 
revealed the beneficial effects of BCA against oxidative stress in diabetes. 
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Type 1 diabetes is an autoimmune disorder 
caused by a destruction of pancreatic beta cells by 
immune cells (1). Pancreatic β-cell destruction 
usually leads to absolute insulin deficiency and 
impaired glucose homeostasis (2). 
Diabetes is one of most challengeable 
health issue nowadays (1). In 2017, almost 370 
thousand Americans were diagnosed with type 1 
diabetes, which is about 10% of all people with 
diabetes (2). Taking insulin is the best treatment for 
type 1 diabetics; however, it is difficult to maintain 
the glucose level close to normal to delay or prevent 
complications (3). Cardiovascular disease, 
neuropathy, nephropathy and retinopathy are the 
main complications of diabetes that directly or 
indirectly are associated with a high blood glucose 
level (4). Hyperglycemic patients are affected by 
microvascular and macrovascular complications 
through different pathways including: 1) increase the 
activity of polyol pathway, 2) protein kinase C 
activation, 3) advanced glycation products formation 
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and 4) increase hexosamine pathway flux (5). 
Although, the insulin deficiency is the primary 
metabolic defect of type 1 diabetes, a number of 
studies have reported that various levels of insulin 
resistance also exist in type 1 diabetic patients (6, 
7). Adipocytes are endocrine cells in adipose tissue 
that secret different adipokines that play important 
roles in glycemic control (8, 9). 
Adiponectin is one of the important 
adipokines secreted by adipocytes that has 
hypoglycemic properties and prevents insulin 
resistance. Several studies have shown that in 
obesity and insulin resistance, adiponectin level 
reduced (10). Resistin is another adipokine that 
belongs to the family of cysteine-rich proteins that 
secretes from adipocytes and reduces the insulin 
sensitivity (11). Furthermore, various studies 
suggested systemic oxidative stress could be 
induced by obesity, consequently, causing 
dysregulation of adipokines and metabolic 
syndrome and diabetes development (12). 
Increased oxidative stress is an extensively 
endorsed participant in the progression and 
development of diabetes and its complications. 
ROS produced by the mentioned pathways causes 
oxidative stress and lack of endogenous antioxidant 
agent lead to cell damage (5, 13). GSH as an 
endogenous defense against oxidative stress, is 
made from three amino acids include cysteine, 
glutamic acid and glycine. Its antioxidant action is 
through oxidation and reduction in the thiol group 
in its structure. GGT enzyme, which directly 
involves in the metabolism of GSH, is found in the 
cell membrane and regulates the GSH level (14). 
Traditional medicine has been used to treat 
different diseases for many years worldwide. Using 
herbal medicine to reduce blood glucose and 
improvement of hyperlipidemia has been examined 
for a long time by diabetic patients (15). Flavonoids 
are the most abundant part of the plants that has 
been identified; using this plant ingredient due to its 
estrogenic properties leads to hypolipidemia and 
can improve diabetes curing. Additionally, 
antioxidant property of these derivatives is well 
proven. BCA is a methylated form of Soy 
isoflavone which is found in red clover, 
cabbage, and alfalfa. BCA shows different 
pharmacological properties such as anticancer, 
antidiabetic, anti-inflammatory, antiallergic, 
hepatoprotective, and neuroprotective (16). 
Additionally, previous studies revealed that BCA is a 
potent radical scavenger (17). Hence, regarding to 
the antioxidant properties of BCA, we examined the 
effect of BCA on the secreted adipokines, insulin 
levels and insulin resistance index or HOMA-IR 
(Homeostatic Model Assessment of Insulin 
Resistance) in type 1 diabetic rats. 
Methods 
Animals. Forty male Wistar rats (body 
weight 200-250 g) were purchased and maintained at 
a controlled temperature (22±4 °C) and 12-hour 
light/dark period conditions. Animals were fed with 
standard water and chow during the study. The ethics 
committee of Arak University of Medical Sciences 
approved the protocol of this animal study (project 
number 93-186-28). 
Diabetes Induction. To induce type 1 
diabetes Streptozotocin (STZ) powder was dissolved 
in citrate buffer (pH=4.5) and the injection was 
performed intraperitoneally (55 mg/kg body weight). 
Seventy two hours after injection, to confirm the 
development of diabetes, fasting blood samples were 
taken from the rats and blood sugar was measured 
using a glucometer. The animals having FBG 250 
mg/dl or higher were considered diabetic (18). Blood 
samples were taken from the tail vein of animals 
(19). 
Examination Procedures. Animals were 
divided randomly into 5 groups (n=6). BCA (Sigma) 
was dissolved in 5% dimethyl sulfoxide (DMSO) and 
administrated orally (10 and 15 mg/kg bw) using 
gavage syringe for 42 days. 
The groups were as follows; Group 1: 
Healthy control (5% DMSO), Group 2: Healthy 
control + BCA (10 mg/kg), Group 3: Diabetic control 
(5% DMSO), Group 4: Diabetic + BCA (10 mg/kg), 
Group 5: Diabetic + BCA (15 mg/kg). 
After 42 days treatment and following 12 
hours fasting, the animals were anesthetized using 
intraperitoneal injection of ketamine and xylazine. 
Blood samples were taken from a vein in their hearts 
and then serum was separated and frozen at -20 °C. 
The body weight of the rats was measured before and 
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after treatment. 
Biochemical Analysis. Serum insulin was 
measured using ELISA kit (Bioassay technology 
laboratory Shanghai, China). 
Insulin resistance index HOMA-IR was 
calculated as follows (20): 
  
Insulin (µU/ml) × glucose (mmol/L)/22.5 
 
Resistin and adiponectin were measured 
using ELISA kits purchased from Shanghai Crystal 
D Biotech companies (China). To compare 
metabolic condition in study groups, serum level of 
glucose was measured using an enzymatic method. 
The activity of AST, ALT and GGT 
enzymes were measured using commercial 
colorimetric kits (Pars Azmun, Tehran, Iran) and a 
spectrophotometer (JENWAY 6505, Europe 
Union). Serum GSH was measured using 
colorimetric kits (Nanjing Jiancheng 
Bioengineering Institute, Nanjing, China). 
Statistical Analysis. Statistical analysis of 
obtained data was performed using SPSS software, 
version 16. Firstly, the data distribution in each 
group was assessed for normality and then the 
statistical comparison was carried out using 
ANOVA test and post hoc Tukey test. In all 
statistical analyzes p-value less than 0.05 was 
considered significant. 
Results 
The Effect of BCA on FBS. In this study, 
fasting blood glucose (FBG) was measured at the 
beginning and end of the study, our results showed 
that FBG levels significantly increased in diabetic 
rats compared to healthy control rats (p<0.05). A 
comparison of blood glucose levels in treated 
groups with doses of 10 and 15 mg/kg BCA and the 
diabetic control group showed significantly lower 
level (p=0.001) in treated groups. However, 
comparing the two treated groups (10 & 15 mg/kg 
BCA), no significant differences in FBG after 6 
weeks of treatment was observed (Fig. 1). 
Moreover, our results revealed that diabetic rat’s 
body weight (BW) was decreased significantly. 
Oral administration of BCA at two different doses 
(10 & 15 mg/kg BCA) improved BW; however, the 
difference in gained weight was not statistically 
remarkable. 
The Effect of BCA on Serum Level of 
Adiponectin. As shown in Figure 2, adiponectin level 
in the diabetic group compared with the healthy 
control group was significantly lower (p=0.001). In 
addition, analysis of data showed a significant 
difference in adiponectin level between treated 
groups (doses 10 and 15 mg/kg) and the diabetic 
control group. Adiponectin level in two treated 
groups significantly increased compared to the 
diabetic control group (p=0.001). However, there 
was no significant difference in adiponectin level 
between two treated groups. 
 
 
Figure 1. Comparison of FBSat the start and end of the study: a: 
compare with beginning in same group (p<0.05), b: compare with 




Figure 2. Comparison of serum adiponectin level in study groups a: 
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The Effect of BCA on Serum Level of 
Resistin. As Fig. 3 shows, resistin levels in the 
diabetic control group was significantly increased 
compared to the healthy control group (p=0.001), 
on the other hand, the results showed that resistin 
was significantly lower in treated rats (10 & 15 
mg/kg BCA) than in diabetic control rats (p=0.001). 
There was no significant difference in resistin 
concentrations between two treated groups (10 & 
15 mg/kg BCA). 
 
 
The Effect of BCA on Insulin Level and 
HOMA-IR. In Table 1, results of insulin and insulin 
resistance index (HOMA-IR) are shown; as these 
data show, the concentration of insulin in the 
diabetic group was significantly lower than that of 
the healthy control group (p=0.001). Also, analysis 
showed that insulin levels were significantly 
increased in two treated groups (doses 10 and 15 
mg/kg). No difference was observed in the insulin 
level between the two treatment groups (doses 10 
and 15 mg/kg). Clearly, in the diabetic control group, 
HOMA-IR increased significantly compared to the 
healthy control group (p=0.001). Moreover, HOMA-
IR remarkably decreased in treated groups (doses 10 
and 15 mg/kg) when compared with diabetic control 
(p<0.05). This index in the treated group with BCA 
doses of 10 was less than that of the treated group 
with the higher dose of BCA; however, the 
difference between the treatment groups was not 
statistically significant.  
The Effect of BCA on GGT Enzyme 
Activity. As shown in Table 1, analysis of the results 
demonstrated that the activity of GGT enzyme 
remarkably elevated in the diabetic control group 
compared to the healthy control group (p=0.001). 
Also, a significant decrease in GGT was observed in 
the two treated groups (10 & 15 mg/kg BCA) 
compared with the diabetic control group (p<0.05). 
However, no significant differences were observed in 
GGT activity between two groups that treated with 
different doses of BCA. 
The effect of BCA on GSH level. There was 
a significant difference in the mean of the GSH level 
between the study groups (p=0.001). GSH in the 
diabetic control group significantly reduced in 
comparison with the healthy control group 
(p=0.001). In both treatment groups, there was a 
significant increase in the concentration of GSH level 
compared to the diabetic control group (p=0.001) 
(Table 1). 
 
Figure 3. Comparison of serum resistin level in study groups. 
Data analysis showed that resistin level increased in diabetic rats 
(p=0.001), a: compare with control (p<0.05), b: compare with 




Table1. Effect Biochanin A on serum insulin level, HOMA-IR index, GGT activity and GSH level in healthy, type 1 diabetic and 
treated diabetic groups. 
Groups Healthy control 
Healthy control+BCA 10 
mg/kg 





HOMA-IR index 2.78 ± 0.09 2.91 ± 0.13a 12.56 ± 1.99a 10.71 ± 0.98ab 11.75 ± 0.45b 
Insulin(mIU/L) 4.5 ± 0.25 3.6 ± 0.55 2.45 ± 0.45a 4.58 ± 0.49ab 4.0 ± 0.52 b 
GGT (U/L) 2.16 ± 0.40 2.33 ± 0.5 30 ± 4.24 a 25.33 ± 1.36ab 24.85 ± 3.89 ab 
GSH (μmol/ml) 0.803 ± 0.031 0.760 ± 0.024 0.694 ± 0.016a 0.739 ± 0.039 ab 0.746 ± 0.021ab 
Results are presented as mean ± SD. BCA, Biochanin A; GGT, Gamma-Glutamyl transferase; GSH, Glutathione 
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In this study, antidiabetic properties of 
BCA were examined in healthy and STZ- induced 
diabetic rats. STZ, a drug with various functions, 
due to its toxicity on β cells islets of Langerhans of 
the pancreas, interferes with the oxidative 
mechanisms of cells leads to diabetes mellitus in 
animal models (21). 
 Diabetes mellitus as an important 
metabolic disorder was characterized by insulin 
secretion deficiency or defect in insulin function 
which results in hyperglycemia. As well as the 
chronic hyperglycemia caused by insulin deficiency 
is linked to long-term dysfunction, damage of 
various organs. 
Type 1 diabetes mainly caused by insulin 
secretion deficiency is associated with damage to β 
cells which eventually results in weight loss. In fact, 
inability to use glucose in insulin sensitive cells and 
protein synthesis is the main weight loss reason 
(22). Our finding has demonstrated that type 1 
diabetes caused weight loss in diabetes induced rats, 
however, in this study results revealed that BCA 
treatment caused weight gain over the treatment 
period. Although, this weight increases did not 
reach to the healthy controls weight; there was a 
remarkable difference in BW between treated 
groups and healthy controls (Fig. 2). According to 
recent studies reports, BCA improves the function 
and secretion of insulin, which it suggested that the 
BCA consumption leads to gained weight 
associated by improving glucose metabolism. 
Previous studies reported that type 1 diabetes leads 
to weight loss in result of proteolytic degradation 
and loss of ATP and energy as well as lack of 
protein synthesis (23). 
The results of present study showed that 
BCA treatment reduced serum glucose in type 1 
induced rats; BCA antidiabetic properties in type 1 
diabetes associated with increasing the insulin 
production in remnant β cells. In accordance with 
present study results, Harni and colleague showed 
that BCA consumption reduces blood glucose 
levels; they suggested that the glucose level decline 
could be caused by insulin secretion increment (21). 
On the other hand, Insulin assay in our study showed 
that BCA consumption increased insulin secretion. 
Moreover, HOMA-IR was higher in the diabetic 
group compared to other groups that received BCA; 
these results confirm the BCA effects on insulin 
secretion. Various studies have reported that 
flavonoids’ anti-diabetic properties could improve 
insulin resistance; also it increases insulin secretion 
from pancreatic beta cells (24, 25). Flavonoids’ anti-
diabetic effects carried out based on different 
mechanisms in various cells especially in pancreatic 
beta cells, these mechanisms mainly includes: 
increasing insulin secretion to reduce hyperglycemia 
by improving glucose metabolism in the hepatocytes, 
increasing glucose uptake in adipose tissue and 
skeletal muscle, also reduced β-cell apoptosis and 
increased the cell proliferation are the main 
mechanisms which are improved by Flavonoids (15). 
Elevated adiponectin secretion is one of the 
important factors that lead to enhanced insulin 
function in skeletal muscle cells. Adiponectin as an 
adipose tissue secreted hormone could improves 
insulin function in insulin dependent cells such as 
skeletal muscle cells. In this way, adiponectin binds 
to its specific receptor and activates the AMPK and 
PPAR-α and then resulting in enriched insulin 
function. Therefore, adiponectin reducing has a 
negative effect on insulin function (26, 27). Our 
finding showed that BCA administration increased 
the adiponectin secretion. Resent findings revealed 
that BCA and Thiazolidinediones could act as a 
PPAR-γ agonists and raise the adiponectin 
production, then improve the insulin function (28). In 
accordance to present study results Ghadimi et al. 
showed that intraperitoneal and oral administration 
of BCA in type 2 diabetic rats increased insulin 
secretion and decreased insulin resistance (29). 
 Resistin is also another adipokine derived 
from adipocytes that has an important role in 
pathophysiology of diabetes. Our study showed that 
resistin increased in diabetic group compared to the 
control group; these changes are parallel to the 
results of glucose and HOMA-IR and BW. Resistin 
levels also significantly decreased in the BCA treated 
groups compared with diabetic control group. In 
accordance with present study results, recent study 
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which is carried out by Asterholm and colleague 
demonstrated that increased resistin level could play 
an important role in insulin resistance (30). Resistin 
as an important adipocyte derived chemokine could 
acts as an inflammatory agent and leads to insulin 
resistance and also it could improves the risk of 
diabetes and cardiovascular diseases (31). It has 
been reported that in diabetic patients’ resistin level 
is higher; in these diabetic patients resistin acts as 
an insulin antagonist which leads to oxidative stress 
induced by glucose toxicity (32). From this view, 
high glucose associated with type 1 and type 2 
diabetes induced oxidative stress-damage (33). 
Our results indicated that the diabetic 
group had higher GGT activity than healthy control. 
Also results showed that GSH remarkably 
decreased in diabetic rats. GSH and GGT 
considered as two oxidative stress markers mainly 
altered in diabetic patients. GSH as an important 
cellular defense against oxidative stress basically 
regulated by GGT enzyme (34). Decreased GSH 
level with a concurrent increase in GGT activity in 
diabetic rats strongly suggest the diabetes induced 
oxidative stress. On the other hand, Consumption of 
BCA as an antioxidant compound improves the 
antioxidant condition in treated rats. It has been 
reported that, BCA consumption and its antioxidant 
properties are closely paralleled by the alteration in 
GGT activity and GSH level. Ravuri et al. showed 
that GGT gene expression increases in cells 
resulting in mitochondrial oxidative stress (35). 
GSH as another oxidative stress marker that 
possesses an important cellular defense against 
oxidative stress is used to prevent the lipid 
peroxidation and oxidative stress in diabetic 
patients and decrease in GSH level is a risk factor 
for diabetes (36). In accordance with our study, the 
results of Ansely et al. showed that hyperglycemia 
related to diabetes is significantly associated with 
decreased GSH level and depilation of GSH in 
diabetic patients favors damage caused by high 
glucose (37, 38). 
Additionally, in present study, we found 
that liver damage caused by toxic agents such as 
STZ (39) is prevented by using natural antioxidants 
component such as BCA. In this study, the rats with 
type 1 diabetes had much more ALT and AST 
activities compared to healthy rats. While in diabetic 
rats received BCA, the activity of the liver enzyme 
decreased significantly which indicates a protective 
effect of BCA against induced liver damage. Our 
previous results showed that STZ could induce 
higher ALT and AST activity in type 1 diabetic rats 
in comparison with normal rates, and using 
flavonoids could exert liver protective effects in STZ 
induced type 1 diabetes (20).  
CONCLUSION 
It can be concluded that BCA as a natural 
antioxidant agent could have beneficial effect on 
insulin secretion, insulin sensitivity and antioxidant 
status in type 1 diabetic rats. Furthermore, the oral 
administration of BCA can control the secretion of 
adipocytes derived hormones such as adiponectin 
and resistin which have a vital role on the initiation 
and development insulin resistance.  
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